Characteristics | PSN (n = 958) | SN (n = 665) | P |
---|---|---|---|
Age | 59.44 ± 10.08 | 60.54 ± 10.53 | 0.034 |
Gender: female | 609 (63.6%) | 347 (52.2%) | < 0.001 |
Smoking | 131 (13.7%) | 156 (23.5%) | < 0.001 |
ASA score | Â | Â | Â |
 I | 350 (36.5%) | 220 (33.1%) | < 0.001 |
 II | 533 (55.7%) | 353 (53.1%) |  |
 III | 75 (7.8%) | 92 (13.8%) |  |
Hypertension | 305 (31.8%) | 226 (34.0%) | 0.394 |
Diabetes | 83 (8.7%) | 89 (13.4%) | 0.003 |
Coronary heart disease | 48 (5.0%) | 48 (7.2%) | 0.081 |
Chronic respiratory diseases | 34 (3.5%) | 23 (3.5%) | 1 |
Tumor location | Â | Â | 0.001 |
 RUL | 356 (37.2%) | 185 (27.8%) |  |
 RML | 75 (7.8%) | 54 (8.1%) |  |
 RLL | 142 (14.8%) | 117 (17.6%) |  |
 LUL | 241 (25.2%) | 168 (25.3%) |  |
 LLL | 144 (15.0%) | 141 (21.2%) |  |
Total tumor size (cm) | 2.06 ± 0.88 | 1.95 ± 0.59 | 0.007 |
Solid size (cm) | 1.06 ± 0.65 | 1.95 ± 0.59 | < 0.001 |
CTR | 0.51 ± 0.22 | 1.00 ± 0.00 | < 0.001 |
Surgical procedure |  |  | < 0.001 |
 Sublobar | 294 (30.7%) | 97 (14.6%) |  |
 Lobar | 664 (69.3%) | 568 (85.4%) |  |
Pathological size (cm) | 1.60 ± 0.71 | 1.84 ± 0.71 | < 0.001 |
Histological types |  |  | < 0.001 |
 ADC | 951 (99.3%) | 599 (90.1%) |  |
 SCC | 1 (0.1%) | 41 (6.2%) |  |
 Others | 6 (0.6%) | 25 (3.8%) |  |
Evaluated lymph nodes | 11.41 ± 4.54 | 12.10 ± 4.90 | 0.004 |
Lymph node metastasis | 26 (2.7%) | 144 (21.7%) | < 0.001 |
N1 station metastasis | 20 (2.1%) | 118 (17.7%) | < 0.001 |
N2 station metastasis | 15 (1.6%) | 93 (14.0%) | < 0.001 |
Skip lymph node metastasis | 6 (0.6%) | 26 (3.9%) | < 0.001 |
Number of metastatic lymph node | 3 | 3.65 | 0.230 |
Pleural invasion | 71 (7.4%) | 140 (21.1%) | < 0.001 |
Bronchi invasion | 6 (0.6%) | 44 (6.6%) | < 0.001 |
Solid component | 53 (5.7%) | 131 (21.0%) | < 0.001 |
Micropapillary component | 38 (4.1%) | 87 (13.9%) | < 0.001 |
Ki-67 expression level | 12.86 ± 11.38 | 30.02 ± 23.57 | < 0.001 |
EGFR mutation a |  |  | < 0.001 |
 Wild type | 95 (21.7%) | 101 (38.7%) |  |
 Mutant type | 342 (78.3%) | 160 (61.3%) |  |
ALK fusion a | Â | Â | Â |
 No | 181 (98.9%) | 96 (94.1%) | 0.049 |
 Yes | 2 (1.1%) | 6 (5.9%) |  |
ROS1 fusion a | Â | Â | Â |
 No | 181 (100.0%) | 95 (97.9%) | 0.232 |
 Yes | 0 | 2 (2.1%) |  |
Adjuvant therapy | 107 (11.2%) | 241 (36.2%) | < 0.001 |